An anti-cancer composition for delivering a 5-fluorouracil to cancer tissues in a warm-blooded animal, wherein the cancer is a cancer sensitive to 5-fluorouracil. The composition comprises uracil or a pharmaceutically acceptable salt thereof, and a 5-fluorouracil pro drug selected from the group consisting of 1, 3-bis (2-tetrahydrofuryl)-5-fluorouracil and 3-(2-tetrahydrofuryl)-5-fluorouracil in a small amount of about 0.1 to less than 0.1 mole per mole of uracil or salt thereof.

An anti-cancer composition for treating cancers sensitive to 5-fluorouracil therapy in warm-blooded animals, comprising 5-fluorouracil and uracil.

An anti-cancer composition for delivering 5-fluorouracil to cancer tissues in a warm-blooded animal, wherein the cancer is a cancer sensitive to 5-fluorouracil, comprising 1-n-hexylcarbamoyl-5-fluorouracil and uracil (or salt there-of), wherein the composition contains less than 0.1 mole of the 5-fluorouracil per mole of the uracil.

An anti-cancer composition for delivering 5-fluorouracil to cancer tissues which comprises at least one 5-fluorouracil derivative, and a uracil derivative.

5-Fluorouracil nitroxyl derivatives of the general formula: ##STR1## wherein R.sub.1 =R.sub.2 =X, ##STR2## or R.sub.1 =X, R.sub.2 =H, or R.sub.1 =H, R.sub.2 =X, or R.sub.1 =Na, R.sub.2 =X, possessing an antitumor activity.

Highly selective and high yield process for producing antitumor agent 1-phthalidyl-5-fluorouracil derivatives of formula (I) which comprises reacting a phthalidyl compound (II) with an amine (III) to yield the quaternary ammonium salts (IV), and reacting the latter with 5-fluorouracil. ##STR1## [wherein X is leaving group; ##STR2## is triethylamine, N-methylmorpholine, N-ethylmorpholine, and the like; R.sup.4 and R.sup.5 each is hydrogen, trialkylsilyloxy, alkoxy, nitro, cyano, carboxy, or alkox...

A composition containing a pharmacologically effective amount of 1,3-bis(2-tetrahydrofuryl)-5-fluorouracil and an excipient for delivering 5-fluorouracil to cancer cellular tissue of a cancer sensitive to 5-fluorouracil therapy.

The present invention relates to a superficial therapeutic system consisting of an impermeable backing layer, an active substance containing matrix, and a removable protective layer, in which the matrix comprises: a. antineoplastic active substance b. a self-adhesive polyacrylate c. a water absorber and optionally d. a non-adhesive hydrophilic polyacrylate e. a softener and/or penetration accelerator.

A process for efficiently preparing 1-(2-tetrahydrofuryl)-5-fluorouracil useful as an antitumor agent or an antiviral agent which comprises reacting 5-fluorouracil with 2,3-dihydrofuran. This reaction proceeds advantageously in the presence of a reaction accelerator such as a Lewis acid in a polar solvent such as pyridine.

5-Fluorouracil compounds having a glycoside substituent connected to the 5-fluorouracil nucleus through a bridging oxygen atom; and having anti-tumor activity.